WO2001092464A3 - Therapeutic vaccine preparation and treatment for hiv viral infection - Google Patents

Therapeutic vaccine preparation and treatment for hiv viral infection Download PDF

Info

Publication number
WO2001092464A3
WO2001092464A3 PCT/NL2001/000431 NL0100431W WO0192464A3 WO 2001092464 A3 WO2001092464 A3 WO 2001092464A3 NL 0100431 W NL0100431 W NL 0100431W WO 0192464 A3 WO0192464 A3 WO 0192464A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
hiv
treatment
treating
viral infection
Prior art date
Application number
PCT/NL2001/000431
Other languages
French (fr)
Other versions
WO2001092464A2 (en
Inventor
Charles Edward Strother Iii
George Francis Kamen
Original Assignee
Charles Edward Strother Iii
George Francis Kamen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charles Edward Strother Iii, George Francis Kamen filed Critical Charles Edward Strother Iii
Priority to AU2001274661A priority Critical patent/AU2001274661A1/en
Publication of WO2001092464A2 publication Critical patent/WO2001092464A2/en
Publication of WO2001092464A3 publication Critical patent/WO2001092464A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention is a therapeutic treatment which includes a vaccination preparation method that uses the specific host HIV virus as the antigen template for creating a conjugate complex. This invention discloses the method for treating the HIV virus with Acrolein as hereinafter described and the administration thereof singularly and or in combination with additional therapies to cure patients specially exhibiting the classical AIDS syndrome. This method consists of deriving individual host virus strains from each and every infected host separately and using the hosts virus to initiate their own immune response. The presented invention is directly related to therapeutic methods for treating retro-viral infections such as the (HIV) Human Immunodeficiency Virus.
PCT/NL2001/000431 2000-05-31 2001-05-31 Therapeutic vaccine preparation and treatment for hiv viral infection WO2001092464A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001274661A AU2001274661A1 (en) 2000-05-31 2001-05-31 Therapeutic vaccine preparation and treatment for hiv viral infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1015352A NL1015352C2 (en) 2000-05-31 2000-05-31 Antigen conjugation vaccination technique with host virus.
NL1015352 2000-05-31

Publications (2)

Publication Number Publication Date
WO2001092464A2 WO2001092464A2 (en) 2001-12-06
WO2001092464A3 true WO2001092464A3 (en) 2002-04-11

Family

ID=19771480

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2001/000431 WO2001092464A2 (en) 2000-05-31 2001-05-31 Therapeutic vaccine preparation and treatment for hiv viral infection

Country Status (3)

Country Link
AU (1) AU2001274661A1 (en)
NL (1) NL1015352C2 (en)
WO (1) WO2001092464A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU1824196C (en) * 1991-02-25 1993-06-30 Всесоюзный научно-исследовательский ветеринарный институт Method for production of inactivated antigen of rabies virus to provide serologic reactions
WO1993014197A1 (en) * 1992-01-16 1993-07-22 New York University Hypericin treatment of vaccine agents for improved immunogenicity
EP0562877A2 (en) * 1992-03-27 1993-09-29 ORTHO DIAGNOSTIC SYSTEMS INC. (a New Jersey corp.) Cell fixative and method of staining cells without destroying the cell surface

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU1824196C (en) * 1991-02-25 1993-06-30 Всесоюзный научно-исследовательский ветеринарный институт Method for production of inactivated antigen of rabies virus to provide serologic reactions
WO1993014197A1 (en) * 1992-01-16 1993-07-22 New York University Hypericin treatment of vaccine agents for improved immunogenicity
EP0562877A2 (en) * 1992-03-27 1993-09-29 ORTHO DIAGNOSTIC SYSTEMS INC. (a New Jersey corp.) Cell fixative and method of staining cells without destroying the cell surface

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 9444, Derwent World Patents Index; AN 1994-356531, XP002167695 *
G. KAMEN: "Acrolein and Mengo-Semliki virus immunity.", NATURE, vol. 192, 9 December 1961 (1961-12-09), London, GB, pages 986 - 987, XP000993519 *
G. KAMEN: "Detection of acrolein by quantitative immunochemical analysis.", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 72, 1949, San Diego, CA, USA, pages 18 - 21, XP000993499 *
U. BACHRACH ET AL.: "Antivirus action of acrolein, glutaraldehyde and oxidized spermine.", JOURNAL OF GENERAL VIROLOGY, vol. 13, no. 3, December 1971 (1971-12-01), London, GB, pages 415 - 422, XP000993502 *
U. BACHRACH ET AL.: "Effect of oxidized spermine and other aldehydes on the infectivity of vaccinia virus.", APPLIED MICROBIOLOGY, vol. 23, no. 2, February 1972 (1972-02-01), Washington, DC, USA, pages 232 - 235, XP000993498 *

Also Published As

Publication number Publication date
WO2001092464A2 (en) 2001-12-06
NL1015352C2 (en) 2001-12-03
AU2001274661A1 (en) 2001-12-11

Similar Documents

Publication Publication Date Title
WO2001068117A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
CA2632516C (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
CY1105408T1 (en) USE OF PARAPOX OVIS VIRUS STRAINS FOR THE PREPARATION OF ANCIENT MEDICINES AND ANTI-CANCER DRUGS
WO2002022686A3 (en) Defensin-antigen fusion proteins
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
BG98522A (en) Peptides including cytotoxic t-lymphocytic response to the virus of hepatite b
DE60331412D1 (en) HIV vaccine and method of administration
BR0316291A (en) Hcv vaccine, methods of preventing or treating an hcv infection in a mammal and vaccinating an individual, and using a hcv vaccine
WO2003061602A3 (en) Combination therapy for treatment of hiv infection
WO2002022687A3 (en) Viral chemokine-tumur antigen fusion proteins
Moingeon et al. Therapeutic vaccines against infectious diseases
WO2001092464A3 (en) Therapeutic vaccine preparation and treatment for hiv viral infection
NO890565L (en) PREVENTION AND TREATMENT OF RETROVIRAL DISEASE.
CA2350127A1 (en) Avipox vector coding an hiv antigen and a cytokine
WO2003025002A3 (en) Method and compositions of defensin-antigen fusion proteins and chemokine-antigen fusion proteins as vaccines for tumors and viral infection
BR0207899A (en) Combination immunogen for sequential administration of components to elicit an immune response against papillomavirus, a pharmaceutical product, use of a pharmaceutical product, and method for eliciting an immune response against papillomavirus in a patient
ES2133408T3 (en) NEW ISOLATES OF HIV-1 VIRUSES OF A SUBTYPE, AND THEIR DIFFERENTIAL DIAGNOSIS, VACCINE AGAINST HIV-1 INFECTION OF THIS SUBTYPE AND PROCEDURE TO PREPARE AND USE THE HIV-1 ISOLATE.
WO2004041200A3 (en) Dna based plasmid formulations and vaccines and prophylactics containing the same
RU2682677C2 (en) Method of post-exposure prevention of tick-borne encephalitis
WO2003073984A3 (en) Tat as an immunogen
WO2001054652A8 (en) A method of inducing autovaccination against hiv infection using structured treatment interruptions
WO2005027835A3 (en) Therapeutic immunization of hiv-infected individuals
RU2001125429A (en) TREATMENT OF CHRONIC VIRAL INFECTIONS M. VACCAE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CN IN JP KP KR RU US VN ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CN IN JP KP KR RU US VN ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP